The company showcased multiple in-house drug pipelines and more than 30 international-market products, while using the Shanghai gathering to deepen global business ties.
Kexing Biopharm said it received the “R&D Innovation Award” at CPHI & PMEC China 2026, where it presented several self-developed drug pipelines and more than 30 products for international markets. The June 16-18 event at the Shanghai New International Expo Center featured products spanning oncology, autoimmune diseases and metabolic disorders, including albumin-bound paclitaxel, Bevacizumab, Infliximab, Enzalutamid, Aflibercept, Liraglutid and Semaglutid. The company also highlighted globally innovative pipeline candidates including GB18 for cancer cachexia, GB19/GB26 for systemic lupus erythematosus, GB10 for ophthalmology, and GB20/GB24 for autoimmune diseases. Clinical progress in two Phase III programs - long-acting GC and GB05, an interferon inhalation solution - also drew attention. Kexing Biopharm said its business development team took part in forums and roundtables on global pharmaceutical expansion, using the event to discuss the international commercialization of Chinese biopharmaceutical products and to refine its internationalization strategy. The company also held a June 15 gathering for customers and partners from multiple countries to discuss market dynamics, cooperation prospects and future strategic planning. It said CPHI remains a strategic platform for expanding its global presence and working with international partners to bring more high-quality products to broader overseas markets.